Font Size




Menu Style

AVG Home


AVG Webinar Series

The first of these quarterly 1.5 hrs webinars was successfully held on 25 October.

The Keynote speaker was Dr Cameron R. Wolfe, Duke University Medical Center, NC, USA who spoke onTreatments & Antiviral Therapeutics for COVID – Present and Future’.

The 2 short talks were:

Ensitrelvir, a novel 3C-like protease inhibitor for once daily oral treatment of mild-to-moderate COVID-19 – Dr Takeki Uehara, Shionogi & Co. Ltd.,  Japan

The Preclinical Antiviral Activity of ALG-097558, a Novel, Orally Bioavailable SARS-CoV-2 3CLpro Inhibitor for the Treatment of COVID-19 - Dr Andreas Jekle, Aligos Therapeutics Inc., USA

If you missed the webinar you can listen to it via this link.

Registration is now open for Webinar 2 and further details will be posted here in due course.


7th AVG Conference (in-person)

Registration is now open!

Submit your abstract here

Look out for further details very soon…


Recent Virtual Conference

The ISIRV-WHO virtual conference, held last October, was attended by a global audience of over 730 attendees from 71 countries!  The recordings from this conference are now available here and the Conference Report can be found here.
SARS-CoV-2 / COVID-19   
Antiviral News

AVG Overview

The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More


   isirv Antiviral Group (isirv-AVG) 10th Anniversary

The isirv Antiviral Group was established in 2011 following the merger of the Neuraminidase Inhibitor Susceptibility Network (NISN) with the International Society for Influenza and Other Respiratory Virus Diseases (isirv). Read more

To fulfil its objectives of promoting understanding of the development and clinical use of antivirals against respiratory viruses and the emergence of resistance, the Group has organised a series of AVG conferences on specific topics in different geographical locations plus other smaller specialist meetings and workshops.

The Group gratefully acknowledges the contribution of its partners and the generous financial support from many privateand public organisations that have ensured the success of the Group’s programme of events over the past 10 years.

 Recent AVG Events

Therapeutics for COVID-19, a special virtual conference, 6-8 October 2020
The 3-day programme addressed the latest advances in the development of antivirals and other therapeutics for use against COVID-19 and possibilities for improved clinical management. Oral and e-poster presentations are available. Read more
AVG Polymerase Inhibitor Resistance Meeting, at the Offices of the Task Force for Global Health, Atlanta, USA, 7-8 August 2019
The participants at this small specialist meeting, including public health, academic and corporate representatives who are conducting studies on the new antivirals targeting the influenza RNA polymerase, met to discuss the impact of resistance to these inhibitors. A report of the meeting is incorporated in an Assessment of the Current State of the Art report published in Antiviral Research and now on the AVR journal web site as a highlighted article. Read more
6th ISIRV-AVG Conference: Advances in Respiratory Virus Therapeutics, Washington DC, USA 13-15 November 2018
This conference addressed both pre-clinical and clinical advances in therapeutic and prophylactic agents for influenza, RSV and other respiratory viruses and regulatory issues central to advancing such agents to clinical practice. The report was published in Antiviral Research and can be viewed here.
Highlights from Influenza 2018: Centenary of the 1918 Pandemic, 24-26 June at The Crick, London
The greatest public health disaster in recorded history, the Spanish Flu, began in springtime of 1918 and developed within a few months into a global pandemic with an estimated 50-100 million deaths. By its end, the pandemic had caused a reduction of life expectancy in the US by 12 years, and killed more people than died in the First World War. Read more

Antiviral News


An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance...  read more

Neuraminidase Inhibitors
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020... read more
Clinical Trials & Case Studies
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial... read more
Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment... read more
Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
Baloxavir shows broad-spectrum in vitro replication inhibi­tion of 4 types of influenza viruses; susceptibility pattern is influenza A ˃ B ˃ C ˃ D … read more

Q&A (podcast): Explanation by L. Gubareva (CDC, Atlanta, USA) … listen to podcast 

Baloxavir Marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes
A single, oral dose of baloxavir marboxil was well-tolerated, and rapidly reduced viral titers, but the common emergence of PA/I38T/M-substituted viruses warrants consideration of alternative dosing regimens in young children…read more
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
The kinetics, risk factors, and effects on clinical and virologic outcomes of emergence of PA/I38X-substituted viruses was evaluated. The emergence of viruses with PA/I38X substitutions following baloxavir treatment was associated with transient rises in infectious virus titers, prolongation of virus detectability, initial delay in symptom alleviation, and uncommonly with symptom more
Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS).
A total of 2131 children infected with influenza (683 A/H1N1pdm09; 825 A/H3N2; 623 influenza B) were investigated. Children aged 1>5 years had a higher total viral burden with prolonged virus shedding and had an increased risk of acquiring resistance mutations following antiviral treatment…read more
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial 
This study shows that single-dose baloxavir has superior efficacy to placebo and similar efficacy to oseltamivir for ameliorating influenza symptoms in high-risk outpatients. The safety of baloxavir was comparable to placebo …read more
Clinical outcomes of baloxavir versus oseltamivir in patients hospitalized with
influenza A
In this study of 2392 patients the results support the use of baloxavir for the treatment of influenza A in hospitalized patients with the potential benefit of a faster time to resolution of hypoxia …read more
Efficacy of baloxavir marboxil on household transmission of influenza infection
This study using 169 index patients found that the household secondary attack rate of influenza was comparable in patients treated with baloxavir vs oseltamivir …read more
A universal dual mechanism immunotherapy for the treatment of influenza virus infections
This study describes the synthesis of a small molecule by conjugating the neuraminidase inhibitor, zanamivir, with the highly immunogenic hapten, dinitrophenyl (DNP), which specifically targets the surface of free virus and viral-infected cells … read more
Visit us on:  facebook  twitter